磺达肝癸钠对老年非ST段抬高型急性冠脉综合征的疗效与安全性的研究

目的观察对比磺达肝癸钠和依诺肝素钠对老年非ST段抬高型急性冠脉综合征的临床疗效及安全性。方法将老年非ST段抬高型急性冠脉综合征患者126例分为对照组(62例)治疗组(64例),观察治疗10 d及30 d后两组疗效及安全性。结果 10 d后,治疗组与对照组心血管事件、BNP水平及严重出血的发生例数比较,差异无统计学意义(P0.05)。轻度出血并发症例数均较对照组明显减少(P0.05)。30 d后,治疗组与对照组心血管事件发生情况及BNP水平相比较,仍无统计学差异(P0.05)。严重出血及轻度出血并发症例数均较对照组明显减少(P0.05)。结论磺达肝癸钠治疗老年非ST段抬高型急性冠脉综合征安全有效。

Efficacy and Safety of Fondaparinux on with non-ST Segment Elevation Acute Coronary Syndromes

Objective To observe the clinical efficacy and safety of fondaparinux and enoxaparin for elderly patients with non ST elevation acute coronary syndrome(NSTE-ACS).Methods Elderly patients with NSTE-ACS 126 cases were divided into control group(62 cases)the treatment group (64 cases).Observation on the treatment of 10 days and 30 days after the efficacy and safety of the two groups.Results after l0 days of treatment group and control group of cardiovascular events,BNP level and the number of cases of severe bleeding,the difference was not statistically significant (P ＞ 0.05).Mild bleeding complications were significantly reduced compared with the control group(P ＜0.05)after.30 d.Compared to the treatment group and the control group of cardiovascular events and the level of BNP,still no significant difference (P ＞ 0.05).Severe bleeding and mild bleeding complications were significantly reduced compared with the control group(P ＜ 0.05).Conclusion Fondaparinux in treatment of elderly patients with NSTE-ACS Sign is safe and effective.